| Date Filed | Type | Description |
| 09/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/26/2023 |
4
| TRABER PETER G (Chief Medical Officer) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Sold 705 shares
@ $1.06, valued at
$747.3 |
|
| 08/17/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/17/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/17/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/12/2023 |
SC 13G
| Artal International S.C.A. reports a 6.6% stake in Selecta Biosciences, Inc. |
| 06/01/2023 |
4
| Kishimoto Takashi Kei (Chief Scientific Officer) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Gifted 43,000 shares
@ $0
Gifted 26,500 shares
@ $0 |
|
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 03/21/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| MANGROVE PARTNERS reports a 6% stake in Selecta Biosciences, Inc. |
| 01/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/06/2023 |
4
| Brunn Carsten (President and CEO) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Sold 27,549 shares
@ $1.1337, valued at
$31.2k
Sold 48 shares
@ $1.145, valued at
$55
Sold 13,396 shares
@ $1.1293, valued at
$15.1k
Sold 77 shares
@ $1.115, valued at
$85.9 |
|
| 01/06/2023 |
4
| Johnston Lloyd P. (Chief Operations Officer) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Sold 6,381 shares
@ $1.1337, valued at
$7.2k
Sold 11 shares
@ $1.1401, valued at
$12.5
Sold 3,372 shares
@ $1.1293, valued at
$3.8k
Sold 20 shares
@ $1.1104, valued at
$22.2 |
|
| 01/06/2023 |
4
| Kishimoto Takashi Kei (Chief Scientific Officer) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Sold 6,381 shares
@ $1.1337, valued at
$7.2k
Sold 11 shares
@ $1.145, valued at
$12.6
Sold 3,372 shares
@ $1.1293, valued at
$3.8k
Sold 20 shares
@ $1.1114, valued at
$22.2 |
|
| 01/06/2023 |
4
| TRABER PETER G (Chief Medical Officer) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Sold 8,164 shares
@ $1.1337, valued at
$9.3k
Sold 15 shares
@ $1.142, valued at
$17.1
Sold 3,445 shares
@ $1.1293, valued at
$3.9k
Sold 20 shares
@ $1.1114, valued at
$22.2 |
|
| 01/04/2023 |
4
| Myers Scott Dunseth (Director) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 87,500 options to buy
@ $1.13, valued at
$98.9k
|
|
| 01/04/2023 |
4
| ANDO GORAN (Director) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 75,000 options to buy
@ $1.13, valued at
$84.8k
|
|
| 01/04/2023 |
4
| BARABE TIMOTHY C (Director) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 87,500 options to buy
@ $1.13, valued at
$98.9k
|
|
| 01/04/2023 |
4
| Brunn Carsten (President and CEO) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 282,800 shares
@ $0
Granted 1,275,000 options to buy
@ $1.13, valued at
$1.4M
|
|
| 01/04/2023 |
4
| COX CARRIE SMITH (Director) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 107,500 options to buy
@ $1.13, valued at
$121.5k
|
|
| 01/04/2023 |
4
| DeSilva Nishan M (Director) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 75,000 options to buy
@ $1.13, valued at
$84.8k
|
|
| 01/04/2023 |
4
| Johnston Lloyd P. (Chief Operations Officer) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 100,000 shares
@ $0
Granted 475,000 options to buy
@ $1.13, valued at
$536.8k
|
|
| 01/04/2023 |
4
| Kishimoto Takashi Kei (Chief Scientific Officer) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 100,000 shares
@ $0
Granted 475,000 options to buy
@ $1.13, valued at
$536.8k
|
|
| 01/04/2023 |
4
| Sallin Aymeric (Director) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 75,000 options to buy
@ $1.13, valued at
$84.8k
|
|
| 01/04/2023 |
4
| SPRINGER TIMOTHY A (10% Owner) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 75,000 options to buy
@ $1.13, valued at
$84.8k
|
|
| 01/04/2023 |
4
| TRABER PETER G (Chief Medical Officer) has filed a Form 4 on SELECTA BIOSCIENCES INC|
Txns:
| Granted 200,000 shares
@ $0
Granted 900,000 options to buy
@ $1.13, valued at
$1M
|
|
|